IRIS
COMOLLI, GIUDITTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.274
AS - Asia 952
EU - Europa 724
SA - Sud America 129
AF - Africa 49
Continente sconosciuto - Info sul continente non disponibili 34
OC - Oceania 2
Totale 3.164
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.228
CN - Cina 301
SG - Singapore 258
IT - Italia 184
VN - Vietnam 145
HK - Hong Kong 115
RU - Federazione Russa 112
IE - Irlanda 105
BR - Brasile 87
DE - Germania 85
FI - Finlandia 60
FR - Francia 42
GB - Regno Unito 35
ZA - Sudafrica 34
IN - India 27
SE - Svezia 18
CA - Canada 17
IQ - Iraq 17
MX - Messico 17
PL - Polonia 17
BD - Bangladesh 14
JP - Giappone 12
BE - Belgio 11
UA - Ucraina 11
VE - Venezuela 11
ES - Italia 10
PH - Filippine 9
AR - Argentina 8
ID - Indonesia 8
NL - Olanda 8
TR - Turchia 8
AT - Austria 6
EC - Ecuador 5
PY - Paraguay 5
CL - Cile 4
CO - Colombia 4
CZ - Repubblica Ceca 4
LT - Lituania 4
MA - Marocco 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
BH - Bahrain 3
AL - Albania 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
HN - Honduras 2
IR - Iran 2
JM - Giamaica 2
JO - Giordania 2
KR - Corea 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NP - Nepal 2
PE - Perù 2
PK - Pakistan 2
TN - Tunisia 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AS - Samoa Americane 1
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
LV - Lettonia 1
MN - Mongolia 1
MU - Mauritius 1
MY - Malesia 1
MZ - Mozambico 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TM - Turkmenistan 1
Totale 3.131
Salva come PNG Salva come JPEG
Città #
Dallas 179
Singapore 158
San Jose 151
Ashburn 137
Hong Kong 114
Dublin 101
Beijing 85
Chandler 77
New York 63
Council Bluffs 49
Ho Chi Minh City 48
Munich 48
Milan 44
Los Angeles 43
Helsinki 36
Pavia 36
Boardman 33
Hanoi 29
Johannesburg 29
Lauterbourg 28
Ann Arbor 26
Shanghai 24
Santa Clara 20
Moscow 18
Nanjing 18
Turku 18
Redondo Beach 17
Princeton 16
Buffalo 15
Jacksonville 15
Orem 14
Lawrence 13
Wilmington 13
Warsaw 12
Frankfurt am Main 11
Rome 11
Seattle 11
Tokyo 11
Brooklyn 10
Columbus 10
Medford 10
Poplar 10
Toronto 9
Biên Hòa 8
Brussels 8
Chennai 8
Denver 8
Mexico City 8
Shenyang 8
São Paulo 8
The Dalles 8
Da Nang 7
Hebei 7
Nanchang 7
Stockholm 7
Baghdad 6
San Francisco 6
Amsterdam 5
Chicago 5
Düsseldorf 5
London 5
Corsico 4
Falls Church 4
Hangzhou 4
Jinan 4
Milwaukee 4
Mumbai 4
Piscataway 4
Pune 4
Vũng Tàu 4
Washington 4
Atlanta 3
Belo Horizonte 3
Boston 3
Cascina 3
Changsha 3
Charlotte 3
Guangzhou 3
Ha Long 3
Haiphong 3
Hamad Town 3
Houston 3
Hải Dương 3
Jiaxing 3
Montreal 3
Nha Trang 3
Phoenix 3
Tashkent 3
Tianjin 3
Vigevano 3
Amman 2
Annapolis 2
Bereguardo 2
Bogotá 2
Brescia 2
Buccinasco 2
Bulungan 2
Bắc Giang 2
Bắc Ninh 2
Bến Tre 2
Totale 2.061
Salva come PNG Salva come JPEG
Nome #
Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation 165
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 159
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 150
Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy 142
Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. 135
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 131
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 131
Hyaluronic acid-decorated liposomes as innovative targeted delivery system for lung fibrotic cells 130
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study 121
Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up 117
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up 113
Occult HIV infection in a large sample of health-care users in Lombardy, Italy in 2014-2015: Implications for control strategies 113
Human Cytomegalovirus-Specific Memory CD4+T-Cell Response and Its Correlation with Virus Transmission to the Fetus in Pregnant Women with Primary Infection 107
Dengue Virus-Specific Humoral and T Cellular Immune Response in Italian Residents and Travelers Returning from Endemic Areas 106
Differential Kinetics of Effector and Memory Responses Induced by Three Doses of SARS-CoV-2 mRNA Vaccine in a Cohort of Healthcare Workers 103
Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study 101
Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy 98
Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. 95
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study 94
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment 93
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay 90
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count 89
SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay 85
The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy 84
Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis 83
Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis 83
Performance of new pp65-IGRA for the quantification of HCMV-specific CD4+ T-cell response in healthy subjects and in solid organ transplant recipients 79
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern 70
Memory T cells specific for HBV enumerated by a peptide-based cultured enzyme-linked immunospot assay in healthy HBV-vaccinated subjects 50
Different Antigen-Specific CD4+ and CD8+ T-Cell Response against HCMV Proteins in Pregnant Women with Primary Infection and in Control Subjects with Remote Infection 47
Totale 3.164
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202291 0 2 2 2 4 4 7 8 1 12 9 40
2022/2023284 17 27 2 18 12 19 0 7 120 2 55 5
2023/2024258 24 34 11 9 13 82 26 17 1 8 17 16
2024/2025620 17 34 9 45 13 47 32 22 152 39 74 136
2025/20261.622 104 113 209 185 185 83 317 91 134 94 63 44
2026/2027108 52 56 0 0 0 0 0 0 0 0 0 0
Totale 3.164